Shaanxi Panlong Pharmaceutical Group Co., Ltd. (SHE:002864)
China · Delayed Price · Currency is CNY 20.40
+0.52 (2.62%)
Oct 23, 2026, 3:04 PM CST
SHE:002864 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 2,789 | 3,266 | 3,198 | 4,047 | 3,319 | 2,680 | |
Market Cap Growth | -16.91% | 2.14% | -20.99% | 21.96% | 23.82% | 24.13% |
Enterprise Value | 1,647 | 2,254 | 2,188 | 3,055 | 2,938 | 2,384 |
Last Close Price | 20.40 | 23.40 | 22.75 | 28.58 | 28.68 | 23.05 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 35.35 | 33.92 | 26.59 | 36.65 | 32.81 | 28.77 |
Forward PE | - | 16.47 | 16.47 | 27.59 | 74.31 | 74.31 |
PS Ratio | 2.82 | 2.86 | 3.28 | 4.13 | 3.41 | 3.02 |
PB Ratio | 1.61 | 1.93 | 1.95 | 2.61 | 3.50 | 3.32 |
P/TBV Ratio | 1.65 | 2.00 | 2.02 | 2.71 | 3.79 | 3.65 |
P/FCF Ratio | 18.86 | 158.52 | 42.90 | 97.45 | 47.73 | 75.80 |
P/OCF Ratio | 15.76 | 51.84 | 20.42 | 38.90 | 26.47 | 23.10 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.66 | 1.98 | 2.25 | 3.12 | 3.02 | 2.69 |
EV/EBITDA Ratio | 13.76 | 18.30 | 15.73 | 21.38 | 22.57 | 20.24 |
EV/EBIT Ratio | 20.42 | 25.97 | 20.54 | 27.01 | 25.98 | 23.14 |
EV/FCF Ratio | 11.14 | 109.40 | 29.35 | 73.55 | 42.26 | 67.43 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.03 | 0.06 | 0.09 | 0.07 | 0.45 | 0.18 |
Debt / EBITDA Ratio | 0.45 | 0.82 | 1.09 | 0.71 | 3.25 | 1.20 |
Debt / FCF Ratio | 0.36 | 4.89 | 2.04 | 2.47 | 6.14 | 4.07 |
Net Debt / Equity Ratio | -0.66 | -0.59 | -0.62 | -0.64 | -0.42 | -0.34 |
Net Debt / EBITDA Ratio | -9.59 | -8.07 | -7.32 | -6.99 | -3.04 | -2.34 |
Net Debt / FCF Ratio | -7.73 | -48.24 | -13.65 | -24.06 | -5.70 | -7.79 |
Asset Turnover | 0.42 | 0.50 | 0.44 | 0.48 | 0.60 | 0.71 |
Inventory Turnover | 4.24 | 5.32 | 4.41 | 4.80 | 5.06 | 5.56 |
Quick Ratio | 3.42 | 3.15 | 3.74 | 3.29 | 1.51 | 1.98 |
Current Ratio | 3.66 | 3.44 | 3.97 | 3.49 | 1.64 | 2.19 |
Return on Equity (ROE) | 4.60% | 5.77% | 7.52% | 8.93% | 11.76% | 12.26% |
Return on Assets (ROA) | 2.14% | 2.36% | 3.02% | 3.49% | 4.33% | 5.17% |
Return on Invested Capital (ROIC) | 10.61% | 11.64% | 15.92% | 17.70% | 18.07% | 18.11% |
Return on Capital Employed (ROCE) | 4.40% | 4.80% | 5.80% | 6.90% | 11.00% | 11.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.83% | 2.95% | 3.76% | 2.73% | 3.05% | 3.48% |
FCF Yield | 5.30% | 0.63% | 2.33% | 1.03% | 2.10% | 1.32% |
Dividend Yield | 1.32% | 1.14% | 0.83% | 0.57% | 0.52% | 0.57% |
Payout Ratio | 15.49% | 45.59% | 20.39% | 22.00% | 20.84% | 19.20% |
Buyback Yield / Dilution | 0.16% | -0.06% | -7.01% | -13.03% | -1.16% | 0.60% |
Total Shareholder Return | 1.48% | 1.07% | -6.19% | -12.46% | -0.64% | 1.18% |